Non-tuberculous mycobacteria and the performance of interferon gamma release assays in Denmark.
<h4>Background</h4>The QuantiFERON-TB-Gold Test (QFT) is more specific than the Mantoux skin-test to discriminate between Mycobacterium tuberculosis (MTB) and non-tuberculous mycobacterial (NTM) infections. Here we study the performance of the QFT in patients with NTM disease.<h4>M...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0093986&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849720348656795648 |
|---|---|
| author | Thomas Stig Hermansen Vibeke Østergaard Thomsen Troels Lillebaek Pernille Ravn |
| author_facet | Thomas Stig Hermansen Vibeke Østergaard Thomsen Troels Lillebaek Pernille Ravn |
| author_sort | Thomas Stig Hermansen |
| collection | DOAJ |
| description | <h4>Background</h4>The QuantiFERON-TB-Gold Test (QFT) is more specific than the Mantoux skin-test to discriminate between Mycobacterium tuberculosis (MTB) and non-tuberculous mycobacterial (NTM) infections. Here we study the performance of the QFT in patients with NTM disease.<h4>Methods</h4>From 2005 to 2011, nationwide patient data on positive NTM cultures (n = 925) were combined with nationwide data on QFT results (n = 16,133), both retrieved from the International Reference Laboratory of Mycobacteriology, Denmark. A total of 112 patients with NTM infections had a QFT performed, 53 patients had definite NTM disease, 10 had possible disease and 49 had NTM colonization.<h4>Results</h4>QFT was positive in 8% (4/53) of patients with definite disease, 40% (4/10) with possible disease and 31% (15/49) with colonization. Positivity rate was lowest among patients with definite disease infected with NTM without the RD1 region 4% (2/50). None of the 15 children with MAC lymphadenitis had a positive QFT.<h4>Conclusion</h4>This study is one of the largest assessing IGRAs in patients with NTM disease in a TB low-incidence setting. Our study showed that the QFT holds potential to discriminate between NTM and MTB infections. We found no positive IGRA test results among children with NTM not sharing the RD1-region of MTB resulting in a 100% specificity and we suggest that a QFT in a child presenting with cervical lymphadenitis may be helpful in distinguishing NTM from TB lymphadenitis. |
| format | Article |
| id | doaj-art-b8b79df4ef12477b8b76e9fff356e915 |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-b8b79df4ef12477b8b76e9fff356e9152025-08-20T03:11:57ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0194e9398610.1371/journal.pone.0093986Non-tuberculous mycobacteria and the performance of interferon gamma release assays in Denmark.Thomas Stig HermansenVibeke Østergaard ThomsenTroels LillebaekPernille Ravn<h4>Background</h4>The QuantiFERON-TB-Gold Test (QFT) is more specific than the Mantoux skin-test to discriminate between Mycobacterium tuberculosis (MTB) and non-tuberculous mycobacterial (NTM) infections. Here we study the performance of the QFT in patients with NTM disease.<h4>Methods</h4>From 2005 to 2011, nationwide patient data on positive NTM cultures (n = 925) were combined with nationwide data on QFT results (n = 16,133), both retrieved from the International Reference Laboratory of Mycobacteriology, Denmark. A total of 112 patients with NTM infections had a QFT performed, 53 patients had definite NTM disease, 10 had possible disease and 49 had NTM colonization.<h4>Results</h4>QFT was positive in 8% (4/53) of patients with definite disease, 40% (4/10) with possible disease and 31% (15/49) with colonization. Positivity rate was lowest among patients with definite disease infected with NTM without the RD1 region 4% (2/50). None of the 15 children with MAC lymphadenitis had a positive QFT.<h4>Conclusion</h4>This study is one of the largest assessing IGRAs in patients with NTM disease in a TB low-incidence setting. Our study showed that the QFT holds potential to discriminate between NTM and MTB infections. We found no positive IGRA test results among children with NTM not sharing the RD1-region of MTB resulting in a 100% specificity and we suggest that a QFT in a child presenting with cervical lymphadenitis may be helpful in distinguishing NTM from TB lymphadenitis.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0093986&type=printable |
| spellingShingle | Thomas Stig Hermansen Vibeke Østergaard Thomsen Troels Lillebaek Pernille Ravn Non-tuberculous mycobacteria and the performance of interferon gamma release assays in Denmark. PLoS ONE |
| title | Non-tuberculous mycobacteria and the performance of interferon gamma release assays in Denmark. |
| title_full | Non-tuberculous mycobacteria and the performance of interferon gamma release assays in Denmark. |
| title_fullStr | Non-tuberculous mycobacteria and the performance of interferon gamma release assays in Denmark. |
| title_full_unstemmed | Non-tuberculous mycobacteria and the performance of interferon gamma release assays in Denmark. |
| title_short | Non-tuberculous mycobacteria and the performance of interferon gamma release assays in Denmark. |
| title_sort | non tuberculous mycobacteria and the performance of interferon gamma release assays in denmark |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0093986&type=printable |
| work_keys_str_mv | AT thomasstighermansen nontuberculousmycobacteriaandtheperformanceofinterferongammareleaseassaysindenmark AT vibekeøstergaardthomsen nontuberculousmycobacteriaandtheperformanceofinterferongammareleaseassaysindenmark AT troelslillebaek nontuberculousmycobacteriaandtheperformanceofinterferongammareleaseassaysindenmark AT pernilleravn nontuberculousmycobacteriaandtheperformanceofinterferongammareleaseassaysindenmark |